In vitro activity of apramycin against multidrug-, carbapenem- And aminoglycoside-resistant enterobacteriaceae and acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 74, Issue 4, 2019, Pages 944-952

  Juhas, Mario ^a   Widlake, Emma ^b   Teo, Jeanette ^c   Huseby, Douglas L ^d   Tyrrell, Jonathan M ^b   Polikanov, Yury S ^e   Ercan, Onur ^d   Petersson, Anna ^d   Cao, Sha ^d   Aboklaish, Ali F ^b   Rominski, Anna ^a   Crich, David ^f   Böttger, Erik C ^a   Walsh, Timothy R ^b   Hughes, Diarmaid ^d   Hobbie, Sven N ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^d UPPSALA UNIVERSITY   (Sweden)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; APRAMYCIN; CARBAPENEM; GENTAMICIN; METHYLTRANSFERASE; PLAZOMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; NEBRAMYCIN;

ACINETOBACTER BAUMANNII; AMINOGLYCOSIDE RESISTANCE; ANTIBACTERIAL ACTIVITY; ARTICLE; BROTH DILUTION; CITROBACTER FREUNDII; DRUG ACTIVITY; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GENOTYPE; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORGANELLA MORGANII; MULTIDRUG RESISTANCE; NONHUMAN; PROTEUS MIRABILIS; PROVIDENCIA; SERRATIA MARCESCENS; ACINETOBACTER INFECTION; AFRICA; ANTIBIOTIC RESISTANCE; ASIA; DRUG EFFECT; ENTEROBACTERIACEAE INFECTION; EUROPE; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SOUTH AMERICA; WHOLE GENOME SEQUENCING;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; AFRICA; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; ASIA; CARBAPENEMS; DRUG RESISTANCE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EUROPE; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; NEBRAMYCIN; SOUTH AMERICA; WHOLE GENOME SEQUENCING;

EID: 85062997880     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dky546     Document Type: Article

References (54)

1. Potron A, Poirel L, Nordmann P. Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: mechanisms and epidemiology. Int J Antimicrob Agents 2015; 45: 568-85.
2. Busani S, Serafini G, Mantovani E et al. Mortality in patients with septic shock by multidrug resistant bacteria. J Intensive Care Med 2017; doi: 10.1177/0885066616688165.
3. Poirel L, Kieffer N, Liassine N et al. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of Escherichia coli. Lancet Infect Dis 2016; 16: 281.
4. WHO. Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-resistant Bacterial Infections. Geneva:World Health Organization, 2017 (WHO/EMP/IAU/2017.12).
5. Blair JM, Webber MA, Baylay AJ et al. Molecular mechanisms of antibiotic resistance. Nat RevMicrobiol 2015; 13: 42-51.
6. Fischbach M, Walsh C. Antibiotics for emerging pathogens. Science 2009; 325: 1089-93.
7. Liu YY, Wang Y, Walsh TR et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological andmolecular biological study. Lancet Infect Dis 2016; 16: 161-8.
8. Osei Sekyere J, Govinden U, Bester LA et al. Colistin and tigecycline resistance in carbapenemase-producing Gram-negative bacteria: emerging resistance mechanisms and detection methods. J Appl Microbiol 2016; 121: 601-17.
9. Juhas M. Pseudomonas aeruginosa essentials: an update on investigation of essential genes. Microbiology (Reading, Engl) 2015; 161: 2053-60.
10. Lee SA, Gallagher LA, Thongdee M et al. General and conditionspecific essential functions of Pseudomonas aeruginosa. Proc Natl Acad Sci USA 2015; 112: 5189-94.
11. McCoy LS, Xie Y, Tor Y. Antibiotics that target protein synthesis. Wiley Interdiscip Rev RNA 2011; 2: 209-32.
12. Krause KM, Serio AW, Kane TR et al. Aminoglycosides: an overview. Cold Spring Harb Perspect Med 2016; 6: a027029.
13. Michiels JE, Van den Bergh B, Verstraeten N et al. In vitro emergence of high persistence upon periodic aminoglycoside challenge in the ESKAPE pathogens. Antimicrob Agents Chemother 2016; 60: 4630-7.
14. Karah N, Dwibedi CK, Sjöström K et al. Novel aminoglycoside resistance transposons and transposon-derived circular forms detected in carbapenem-resistant Acinetobacter baumannii clinical isolates. Antimicrob Agents Chemother 2016; 60: 1801-18.
15. Kang AD, Smith KP, Eliopoulos GM et al. In vitro apramycin activity against multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Diagn Microbiol Infect Dis 2017; 88: 188-91.
16. Smith KP, Kirby JE. Evaluation of apramycin activity against carbapenemresistant and -susceptible strains of Enterobacteriaceae. Diagn Microbiol Infect Dis 2016; 86: 439-41.
17. Wachino J, Arakawa Y. Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update. Drug Resist Updat 2012; 15: 133-48.
18. Matt T, Ng CL, Lang K et al. Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin. Proc Natl Acad Sci USA 2012; 109: 10984-9.
19. Clinical Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Tenth Edition: Approved Standard M07-A10. CLSI, Wayne, PA, USA, 2015.
20. Schulthess B, Bloemberg GV, Zbinden A et al. Evaluation of the Bruker MALDI biotyper for identification of fastidious Gram-negative rods. J Clin Microbiol 2016; 54: 543-8.
21. Stucki D, Ballif M, Egger M et al. Standard genotyping overestimates transmission of Mycobacterium tuberculosis among immigrants in a lowincidence country.J ClinMicrobiol 2016; 54: 1862-70.
22. Gupta SK, Padmanabhan BR, Diene SM et al. ARG-ANNOT, a newbioinformatic tool to discover antibiotic resistance genes in bacterial genomes. Antimicrob Agents Chemother 2014; 58: 212-20.
23. Davis JH, Rubin AJ, Sauer RT. Design, construction and characterization of a set of insulated bacterial promoters. Nucleic Acids Res 2011; 39: 1131-41.
24. López-Diaz MD, Culebras E, Rodríguez-Avial I et al. Plazomicin activity against 346 extended-spectrum-b-lactamase/AmpC-producing Escherichia coli urinary isolates in relation to aminoglycoside-modifying enzymes. Antimicrob Agents Chemother 2017; 61: pii: e02454-16.
25. Rodríguez-Avial I, Pena I, Picazo JJ et al. In vitro activity of the nextgeneration aminoglycoside plazomicin alone and in combinationwith colistin, meropenem, fosfomycin or tigecycline against carbapenemaseproducing Enterobacteriaceae strains. Int J Antimicrob Agents 2015; 46: 616-21.
26. Denervaud-Tendon V, Poirel L, Connolly LE et al. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates. J Antimicrob Chemother 2017; 72: 2787-91.
27. Zhang Y, Kashikar A, Bush K. In vitro activity of plazomicin against b-lactamase- producing carbapenem-resistant Enterobacteriaceae (CRE). JAntimicrob Chemother 2017; 72: 2792-5.
28. Hu Y, Liu L, Zhang X et al. In vitro activity of neomycin, streptomycin, paromomycin and apramycin against carbapenem-resistant Enterobacteriaceae clinical strains. Front Microbiol 2017; 8: 2275.
29. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a globalmenace. J Infect Dis 2017; 215: S28-36.
30. MacNair CR, Stokes JM, Carfrae LA et al. Overcomingmcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun 2018; 9: 458.
31. Hombach M, Wolfensberger A, Kuster SP et al. Influence of clinical breakpoint changes from CLSI 2009 to EUCAST 2011 antimicrobial susceptibility testing guidelines onmultidrug resistance rates of Gram-negative rods. J Clin Microbiol 2013; 51: 2385.
32. Jakobsen L, Sandvang D, Jensen VF et al. Gentamicin susceptibility in Escherichia coli related to the genetic background: problems with breakpoints. Clin Microbiol Infect 2007; 13: 830-2.
33. Rosvoll TC, Lindstad BL, Lunde TM et al. Increased high-level gentamicin resistance in invasive Enterococcus faecium is associated with aac(6')Ieaph( 200)Ia-encoding transferable megaplasmids hosted by major hospitaladapted lineages. FEMS Immunol Med Microbiol 2012; 66: 166-76.
34. Jaimee G, Halami PM. Conjugal transfer of aac(60)Ie-aph(200)Ia gene from native species and mechanism of regulation and cross resistance in Enterococcus faecalis MCC3063 by real time-PCR. Microb Pathog 2017; 110: 546-53.
35. Davies J, O'Connor S. Enzymatic modification of aminoglycoside antibiotics: 3-N-acetyltransferase with broad specificity that determines resistance to the novel aminoglycoside apramycin. Antimicrob Agents Chemother 1978; 14: 69-72.
36. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 2011; 66: 48-53.
37. Magalhaes ML, Blanchard JS. The kineticmechanism of AAC3-IV aminoglycoside acetyltransferase from Escherichia coli. Biochemistry 2005; 44: 16275-83.
38. Lovering AM, White LO, Reeves DS. AAC(1): a new aminoglycosideacetylating enzymemodifying the Cl aminogroup of apramycin. J Antimicrob Chemother 1987; 20: 803-13.
39. Ramirez MS, Tolmasky ME. Aminoglycoside modifying enzymes. Drug Resist Updat 2010; 13: 151-71.
40. Sunada A, Nakajima M, Ikeda Y et al. Enzymatic 1-N-acetylation of paromomycin by an actinomycete strain #8 with multiple aminoglycoside resistance and paromomycin sensitivity. J Antibiot (Tokyo) 1999; 52: 809-14.
41. Schmitt E, Galimand M, Panvert M et al. Structural bases for 16 S rRNA methylation catalyzed by ArmA and RmtB methyltransferases. J Mol Biol 2009; 388: 570-82.
42. Doi Y, Wachino JI, Arakawa Y. Aminoglycoside resistance: the emergence of acquired 16S ribosomal RNA methyltransferases. Infect Dis Clin North Am 2016; 30: 523-37.
43. Cox G, Ejim L, Stogios PJ et al. Plazomicin retains antibiotic activity against most aminoglycosidemodifying enzymes. ACS Infect Dis 2018; 4: 980-7.
44. Poirel L, Bonnin RA, Nordmann P. Analysis of the resistome of amultidrugresistant NDM-1-producing Escherichia coli strain by high-throughput genome sequencing. Antimicrob Agents Chemother 2011; 55: 4224.
45. Ho PL, Lo WU, Yeung MK et al. Complete sequencing of pNDM-HK encoding NDM-1 carbapenemase from a multidrug-resistant Escherichia coli strain isolated in Hong Kong. PLoS One 2011; 6: e17989.
46. Rahman M, Prasad KN, Pathak A et al. RmtC and RmtF 16S rRNAmethyltransferase in NDM-1-producing Pseudomonas aeruginosa. Emerg Infect Dis 2015; 21: 2059-62.
47. Poirel L, Goutines J, Aires-de-Sousa M et al. High rate of association of 16S rRNA methylases and carbapenemases in Enterobacteriaceae recovered fromhospitalized children in Angola. Antimicrob Agents Chemother 2018; 62: pii: e00021-18.
48. Polikanov YS, Melnikov SV, Söll D et al. Structural insights into the role of rRNA modifications in protein synthesis and ribosome assembly. Nat Struct Mol Biol 2015; 22: 342-4.
49. Rafailidis PI, Falagas ME. Options for treating carbapenem-resistant Enterobacteriaceae. Curr Opin Infect Dis 2014; 27: 479-83.
50. Shields RK, Clancy CJ, Press EG et al. Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2016; 60: 3187-92.
51. Truelson KA, Brennan-Krohn T, Smith KP et al. Evaluation of apramycin activity against methicillin-resistant, methicillin-sensitive, and vancomycinintermediate Staphylococcus aureus clinical isolates. Diagn Microbiol Infect Dis 2018; 92: 168-71.
52. Mandhapati AR, Yang G, Kato T et al. Structure-based design and synthesis of apramycin-paromomycin analogues: importance of the configuration at the 60-position and differences between the 60-amino and hydroxy series. J Am Chem Soc 2017; 139: 14611-9.
53. Perez-Fernandez D, Shcherbakov D, Matt T et al. 40-O-substitutions determine selectivity of aminoglycoside antibiotics. Nat Commun 2014; 5: 3112.
54. Hobbie SN, Kalapala SK, Akshay S et al. Engineering the rRNA decoding site of eukaryotic cytosolic ribosomes in bacteria. Nucleic Acids Res 2007; 35: 6086-93.